MTS Nutrition Drop Factor Powder - The X Factor in fat loss has arrived!
FOR US DOMESTIC SALES ONLY!
The Fat Burner You Have Been Waiting For. No Fluff. No BS. Just proven results.
in the world are you taking? Looking at the fat burners you have in
your pantry, I am sure we can all say the same thing about the fat
burners. Underdosed, proprietary blends that lead us to wonder what
exactly we are taking. And the Latin names, wow! I actually looked up an
ingredient from a well known fat burner and it literally translates to
“Orange Tree”. No, not a special orange tree in Taiwan or a special
extract from an orange tree, but actual ORANGE TREE! Like the ones you
find in Florida that make that awesome juice. Well, orange juice is
great and all, but will it cause fat loss?
As someone who
wants results from a fat burner and the ability to control dosing to
yield tremendous, tangible results above and beyond any fat burner in
existence. A fat burner with ingredients you can look at, understand,
and also KNOW that the dosing is scientifically validated. After years
of researching and testing the most effective compounds in existence,
MTS Nutrition CEO Marc Lobliner butted heads with some of the greatest
science minds in the industry to create what they feel is the best fat
burner for results, period. Drop Factor™ is here. FAST Fat loss;
long-lasting, 12+ hour energy and TARGETED fat loss are the things that
Drop Factor does better than any other fat burner ever seen, period.
Are you ready for RESULTS?
The ingredients are max dosed with
one caveat, Yohimbine HCl. Yohimbine HCl in its full dosing in Drop
Factor, 2.5mg per serving, is usually very well tolerated. Some can take
more, some less. Studies show that the effective dose is .2mg per
kilogram of bodyweight per day—that is a LOT of Yohimbine HCl and too
much for some people. Also, while the max dose of the other ingredients
covers a wide range of weights and the two genders, Yohimbine HCl, being
weight dependent, requires a varying degree of dosing and also, you
need to ease into the higher dose moreso than other fat burning agents
to assess tolerance. This is why EthiTech Nutrition, MTS Nutrition’s
sister company, has a Yohimbine HCl so once you reach the maximum two
capsules of Drop Factor two times per day, you can still adjust dosing
by simply adding in Yohimbine HCl. It is the most though out fat loss
system ever created!
Cocoa (Theobroma Cacao) Extract (Bean) standardized to 10% Theobromine: 500mg
only does this help decrease appetite and increase fat burning, it also
acts as a vasodilator and diuretic (1). Not only will it aid in fat
loss, but it will also provide that extra bloodflow and PUMP, a welcome
effect while losing fat, alongside the reduction in nasty, excess water
weight! Even cooler, it has even been linked to having an aphrodisiac
effect! (2) All of this alongside a smooth, controlled stimulant release
similar to caffeine make it a must have in any fat burner and with this
adequate, no BS dosing, look out!
granddaddy of them all, Caffeine is the world’s most widely used
stimulant (4). Caffeine is a Central Nervous System (CNS) stimulant
that has been shown to reduce fatigue as well as mobilize fatty acids
resulting in fat loss. (5)
Cayenne Pepper 40HU (Fruit): 150mg
pepper increases thermogenesis (fat loss) by dilating blood vessels and
increasing blood circulation. This helps to transport fatty acids and
be BURNED! Cayenne Pepper is also use to aid digestion and relieve pain.
Coleus Forskohlii Extract (Root) supplying 20% Forskolin (25mg): 125mg
is the powerful active found in the herb Coleus forskohlii and can help
increase lean mass (build muscle) and decrease fat mass (burn fat).
Forskolin activates the enzyme adenylate cyclase, which increases cyclic
adenosine monophosphate (cAMP) levels. The increase in cAMP activates
hormone-sensitive lipase (HSL) which breaks down stored triglycerides
(bodyfat) and releases fatty acids so they can be oxidized and body fat
can be decreased.
Forskolin helps to increase the release of
fatty acids from fat tissue allowing them to be burned for energy,
leading to a decrease in body fat. (8)
Forskolin is also believed
to have thyroid stimulating properties. Thyroid hormones are
responsible for your metabolism. I have even known MANY fitness
competitors who use this herb instead of harsh, prescription thyroid
medications (when no pre-existing medical condition is present).
Increasing thyroid output will accelerate your metabolic rate and lead
to increased fat loss. (8)
To make things even more awesome,
Forskolin may increase testosterone levels in men, but not negatively
affect sex hormones in women. When on decrease calories, this can be A
GREAT SIDE EFFECT and can also help explain how Forskolin prevents
muscle wasting! (9)
Forskolin is a vasodilator. Blood flow is
VITAL for fat loss as blood flow to fat tissue, especially stubborn fat
areas, is vital to the transportation of fatty acids to areas where they
can be burned and can help Yohimbine HCl (explained later) do it’s
SyneLEAN™ Blend (containing Synephrine): 45mg
is found in the Citrus aurantium fruit. This fruit has been used for
hundreds of years. Synephrine can increase metabolic rate and
thermogenesis without any side effects on blood pressure or
cardiovascular health. An increased metabolic rate means more calories
are burned. Synephrine increases the body’s ability to metabolize stored
body fat as well as a decrease in appetite. (10), (11)
Skin Extract [Seed and Skin], Blueberry Extract [Fruit], Raspberry
Powder [Fruit], Cranberry Powder [Fruit], Prune Powder [Fruit], Cherry
Powder [Fruit], Bilberry [Fruit] and Bilberry Extract [Fruit],
Strawberry Powder [Fruit], Broccoli Extract [Whole], Spinach Powder
[Whole], Tomato Powder [Whole], Carrot Powder [Whole], Onion Powder
Not only are antioxidants a pivotal component to
overall health and wellness, but they also decrease the production of
triglycerides thus decreasing fat storage and enhancing fat loss.
Anti-oxidants also increase fat used for energy during exercise, thus causing your body to burn more fat DURING exercise.
The PolyphOrac Blend was designed to contain a high amount of the anti-oxidants research shows to have a fat loss effect.
increases circulation and blood flow to the brain. This aids in the
transport of fatty acids to be burned. Vinpocetine also helps with
mental and cognitive enhancement. (12-49)
Black Pepper Fruit Extract (Bioperine): 5mg
Bioperine is a patented product from Sabinsa Corporation, U.S. Patents No. 5,536,506; 5,744,161; 5,972,382; 6,054,585.
on clinical data, having Bioperine in the digestive system with
supplemented nutrients results in enhanced absorption. Studies show that
when Bioperine is taken with other nutrients, it significantly
increases the absorption of those nutrients. On its own, it may enhance
the body's natural thermogenic activity and assist the digestive system
with supplemented nutrients, resulting in enhanced absorption.
blocks the alpha2 receptor, the receptor responsible for stubborn fat
areas, from being activated. By blocking the alpha2 receptor with
Yohimbine, the negative feedback caused by NE binding to the alpha
receptors is reduced and fatty acid from those stubborn areas are
released and now able to be burned. Yohimbine has been shown to increase
fat loss by increasing the amount of lipid mobilization and oxidation
and blood flow to adipose tissue due to alpha2 antagonism. So Yohimbine
addresses two of the fat burning principles we are trying to address:
alpha2 receptor action and blood flow. The presence of low insulin
found on insulin controlling diets like MachineTrainingSolutions.com
makes Yohimbine work OPTIMALLY!
Thus, Drop Factor contains only
2.5mg Yohimbine HCl per serving. BUT, but adding in EthiTech Yohimbine
HCl at the dosing needed for you, you will get the best results
possible! The scientific dose is to work up to 0.2mg per kilo of
bodyweight per day. This would be 18mg for a 200lb person. This would be
a LOT in the formula, thus we give you this option and it allows you to
work up to this dose. (50-109)
What about TRUTH TO LABEL!?!? Illegal Substances, Recalls?!
have also heard of many effective fat burners removed from the market
for having adulterated and/or ILLEGAL contaminants in their formulas,
such as ADD medication, illegal amphetamines and even mislabeling for
international shipping. Well, with Drop Factor you get what is on the
label. Assurance guaranteed by…
With this assurance, each
ingredient is tested going in for efficacy, microbials and truth to
label. If your product does not have this on the label, don’t trust it!
Not only will you burn tons of fat and feel great, but you will know
what your are taking to help achieve that goal—nuff said!
MTS Nutrition Drop Factor References:
William Marias Malisoff (1943). Dictionary of Bio-Chemistry and
Related Subjects. Philosophical Library. pp. 311, 530, 573. ISBN
2) Kenneth Maxwell (1996). A Sexual Odyssey:
From Forbidden Fruit to Cybersex. New York: Plenum. pp. 38–40. ISBN
3) Joel Hardman & Lee Limbird, ed (2001).
Goodman & Gilman's the pharmacological basis of therapeutics, 10th
ed.. New York: McGraw-Hill. p. 745. ISBN 0-07-135469-7.
4) Lovett, Richard (24 September 2005). "Coffee: The demon drink?". New Scientist (2518). Retrieved 2009-08-03.
5) Bolton, Sanford (1981). "Caffeine: Psychological Effects, Use and Abuse".Orthomolecular Psychiatry 10 (3): 202–211.
6) Ensminger AH, Esminger M. K. J. e. al. Food for Health: A
Nutrition Encyclopedia. Clovis, California: Pegus Press; 1986 1986.
7) Induction of Drug Metabolism by Forskolin, the Role of The Pregnane X Receptor and the PKA Signal Transduction Pathway.
J Pharmacol Exp Ther. 2004 Ding X, Staudinger J. University of Kansas.
8) Shonteh Henderson, Bahrat Magu, Chris Rasmussen, Stacey
Lancaster, Chad Kerksick, Penny Smith, Charlie Melton, Patty Cowan, Mike
Greenwood, Conrad Earnest, Anthony Almada, Pervis Milnor, Terri
Magrans, Rodney Bowden, Song Ounpraseuth, Ashli Thomas, and Richard B
Kreider, Effects of Coleus Forskohlii Supplementation on Body
Composition and Hematological Profiles in Mildly Overweight Women, J Int
Soc Sports Nutr. 2005; 2(2): 54–62. Published online 2005 December 9.
9) Obesity Research (2005) 13, 1335–1343; doi: 10.1038/oby.2005.162
Preuss HG et al. "Citrus aurantium as a thermogenic, weight-reduction
replacement for ephedra: an overview." J Med. 33, 1-4:247-64, 2002.
Gougeon R et al. "Increase in the thermic effect of food in women by
adrenergic amines extracted from citrus aurantium." Obes Res. 13,
12) Spilt A, Weverling-Rijnsburger AW,
Middelkoop HA, et al. Late-onset dementia: structural brain damage and
total cerebral blood flow. Radiology. 2005 Sep;236(3):990-5.
Szakall S, Boros I, Balkay L, et al. Cerebral effects of a single dose
of intravenous vinpocetine in chronic stroke patients: a PET study. J
Neuroimaging. 1998 Oct;8(4):197-204.
14) Szilagyi G, Nagy Z,
Balkay L, et al. Effects of vinpocetine on the redistribution of
cerebral blood flow and glucose metabolism in chronic ischemic stroke
patients: a PET study. J Neurol Sci. 2005 Mar 15;229-230:275-84.
Vas A, Gulyas B, Szabo Z, et al. Clinical and non-clinical
investigations using positron emission tomography, near infrared
spectroscopy and transcranial Doppler methods on the neuroprotective
drug vinpocetine: a summary of evidences. J Neurol Sci. 2002 Nov
16) Wu SN. Large-conductance Ca2+- activated
K+ channels:physiological role and pharmacology. Curr Med Chem. 2003
17) Stolc S. Indole derivatives as neuroprotectants. Life Sci. 1999;65(18-19):1943-50.
Bonoczk P, Gulyas B, dam-Vizi V, et al. Role of sodium channel
inhibition in neuroprotection: effect of vinpocetine. Brain Res Bull.
19) Lendvai B, Zelles T, Rozsa B, Vizi
ES. A vinca alkaloid enhances morphological dynamics of dendritic spines
of neocortical layer 2/3 pyramidal cells. Brain Res Bull. 2003 Jan
20) Chiu PJ, Tetzloff G, Ahn HS, Sybertz EJ.
Comparative effects of vinpocetine and 8-Br-cyclic GMP on the
contraction and 45Ca-fluxes in the rabbit aorta. Am J Hypertens. 1988
Jul;1(3 Pt 1):262-8.
21) Jones OM, Brading AF, McC Mortensen
NJ. Phosphodiesterase inhibitors cause relaxation of the internal anal
sphincter in vitro. Dis Colon Rectum. 2002 Apr;45(4):530-6.
Truss MC, Stief CG, Uckert S, et al. Phosphodiesterase 1 inhibition in
the treatment of lower urinary tract dysfunction: from bench to bedside.
World J Urol. 2001 Nov;19(5):344-50.
23) Mancina R, Filippi S,
Marini M, et al. Expression and functional activity of
phosphodiesterase type 5 in human and rabbit vas deferens. Mol Hum
Reprod. 2005 Feb;11(2):107-15.
24) Szapary L, Horvath B, Alexy
T, et al. Effect of vinpocetin on the hemorheologic parameters in
patients with chronic cerebrovascular disease. Orv Hetil. 2003 May
25) Molnar P, Erdo SL. Vinpocetine is as
potent as phenytoin to block voltage-gated Na+ channels in rat cortical
neurons. Eur J Pharmacol. 1995 Feb 6;273(3):303-6.
D, Fekete I. A systematic review of vinpocetine therapy in acute
ischaemic stroke. Eur J Clin Pharmacol. 1999 Jul;55(5):349-52.
Karpati E, Biro K, Kukorelli T. Investigation of vasoactive agents
with indole skeletons at Richter Ltd. Acta Pharm Hung. 2002;72(1):25-36.
28) Anon. Vinpocetine. Monograph. Altern Med Rev. 2002 Jun;7(3):240-3.
Hadjiev D. Asymptomatic ischemic cerebrovascular disorders and
neuroprotection with vinpocetine. Ideggyogy Sz. 2003 May
30) Balestreri R, Fontana L, Astengo F. A
double-blind placebo controlled evaluation of the safety and efficacy of
vinpocetine in the treatment of patients with chronic vascular senile
cerebral dysfunction. J Am Geriatr Soc. 1987 May;35(5):425-30.
Hindmarch I, Fuchs HH, Erzigkeit H. Efficacy and tolerance of
vinpocetine in ambulant patients suffering from mild to moderate organic
psychosyndromes. Int Clin Psychopharmacol. 1991;6(1):31-43.
Kemeny V, Molnar S, Andrejkovics M, Makai A, Csiba L. Acute and
chronic effects of vinpocetine on cerebral hemodynamics and
neuropsychological performance in multi-infarct patients. J Clin
Pharmacol. 2005 Sep;45(9):1048-54.
33) Bonoczk P, Panczel G,
Nagy Z. Vinpocetine increases cerebral blood flow and oxygenation in
stroke patients: a near infrared spectroscopy and transcranial Doppler
study. Eur J Ultrasound. 2002 Jun;15(1-2):85-91.
34) Dezsi L,
Kis-Varga I, Nagy J, Komlodi Z, Karpati E. Neuroprotective effects of
vinpocetine in vivo and in vitro. Apovincaminic acid derivatives as
potential therapeutic tools in ischemic stroke. Acta Pharm Hung.
35) Feigin VL, Doronin BM, Popova TF,
Gribatcheva EV, Tchervov DV. Vinpocetine treatment in acute ischaemic
stroke: a pilot single-blind randomized clinical trial. Eur J Neurol.
36) Nagy Z, Vargha P, Kovacs L, Bonoczk P. Meta-analysis of Cavinton. Praxis. 1988 September 15;7(9):63-8.
Szatmari SZ, Whitehouse PJ. Vinpocetine for cognitive impairment and
dementia. Cochrane Database Syst Rev. 2003;(1):CD003119.
Pereira C, Agostinho P, Oliveira CR. Vinpocetine attenuates the
metabolic dysfunction induced by amyloid beta-peptides in PC12 cells.
Free Radic Res. 2000 Nov;33(5):497-506.
39) Kiss B, Cai NS,
Erdo SL. Vinpocetine preferentially antagonizes quisqualate/AMPA
receptor responses: evidence from release and ligand binding studies.
Eur J Pharmacol. 1991 Dec 10;209(1-2):109-12.
40) Pilgramm M,
Schumann K. Need for rheologically active, vasoactive and metabolically
active substances in the initial treatment of acute acoustic trauma.
HNO. 1986 Oct;34(10):424-8.
41) Konopka W, Zalewski P,
Olszewski J, Olszewska-Ziaber A, Pietkiewicz P. Treatment results of
acoustic trauma. Otolaryngol Pol. 1997;51 Suppl 25:281-4.
Maliavina US, Ovchinnikov I, Fasenko VP, et al. Cavinton prevention of
neurosensory hypoacousis in patients with different forms of
tuberculosis. Vestn Otorinolaringol. 2003;(3):35-40.
43) Qiu Y,
Kraft P, Craig EC, Liu X, Haynes-Johnson D. Cyclic nucleotide
phosphodiesterases in rabbit detrusor smooth muscle. Urology. 2002
44) Qiu Y, Kraft P, Craig EC, Liu X,
Haynes-Johnson D. Identification and functional study of
phosphodiesterases in rat urinary bladder. Urol Res. 2001
45) Uckert S, Stief CG, Odenthal KP, et al.
Comparison of the effects of various spasmolytic drugs on isolated human
and porcine detrusor smooth muscle. Arzneimittelforschung. 1998
46) Truss MC, Stief CG, Uckert S, et al.
Initial clinical experience with the selective phosphodiesterase-I
isoenzyme inhibitor vinpocetine in the treatment of urge incontinence
and low compliance bladder. World J Urol. 2000 Dec;18(6):439-43.
Hampel C, Gillitzer R, Pahernik S, Melchior SW, Thuroff JW. Drug
therapy of female urinary incontinence. Urologe A. 2005
48) Alberti C. Bladder and cavernous
contractility and relaxation among intracellular messengers, changes in
sarcoplasmatic free calcium and phosphodiesterase activity. Arch Ital
Urol Androl. 2000 Jun;72(2):75-82.
49) Tsuda K, Kinoshita Y,
Nishio I. Synergistic role of progesterone and nitric oxide in the
regulation of membrane fluidity of erythrocytes in humans: an electron
paramagnetic resonance investigation. Am J Hypertens. 2002
50) Starke K, Trendelenburg AU, Limberger N.
Presynaptic a 2-adrenoceptors: subtype determination. In:
"Adrenoceptors: Structure, Function, and Pharmacology", Ruffolo, RR ed.
Harwood Academic Publishers. 1995:99-108.
51) Byland, DB. Subtypes of a 1- and a 2-adrenergic receptors. FASEB J 1992; 6:832-839.
Heible JP, Ruffolo RR, Starke K. Identification, characterization and
subclassification of a 2-adrenoceptors: an overview. In: "a
2-Adrenergic Receptors: Structure, Function and Therapeutic
Implications". Lanier SM, Limbird LE eds. Harwood Academic Press.
53) Raiteri M, Bonanno G, Maura G, et al.
Subclassification of release-regulating a 2-autorecptors in human breain
cortex. Br J Pharmacol 1992; 107:1146-1151.
54) Piascik MT,
Smith MS, Edelmann SE, et al. a 2 and a 1-Adrenergic receptors in the
regulation of peripheral vascular function. In: "a 2-Adrenergic
Receptors: Structure, Function and Therapeutic Implications". Lanier SM
and Limbird LE eds. Harwood Academic Publishers. 1997:171-178.
Trendelenburg AU, Limberger N, Rump LC. a 2-Adrenergic receptors of
the a 2C subtype mediate inhibition of norepinephrine release in human
kidney cortex. Mol Pharmacol 1994; 415:M68-M76.
56) Galitzky J,
Larrouy D, Berlan M, Lafontan M. New tools for human fat cell
alpha2A-adrenoceptor characterization. Identification on membranes and
on intact cells using the agonist [3H]RX821002. J Pharmacol Exp Ther
57) Lafontan M, Berlan M. Fat cell
alpha2-adrenoceptors: the regulation of fat cell function and lipolysis.
Endocr Rev 1995 Dec, 16(6):716-738.
58) Arner P, Kriegholm E,
et al. Adrenergic regulation of lipolysis in situ at rest and during
exercise. J Clinical Invest 1990; 85:893-898.
59) Maurige P, J
Galitzky, M Berlan, M Lafontan. Heterogeneous distribution of beta and
alpha-2 adrenoceptor binding sites in human fat cells from various fat
deposits: functional consequences. Eur J Clin Invest 1987; 17:156-165.
60) Lafontan M, et al. Adrenergic regulation of adipocyte metabolism. Hum Reprod 1997 Oct; 12 Suppl 1:6-20.
Gether U, Lin S, Kobilka BK. Delineating ligand-specific structural
changes in adrenergic receptors by use of fluorescence spectroscopy. In:
"a 2-Adrenergic Receptors: Structure, Function and Therapeutic
Implications". Lanier SM and Limbird LE eds. 1997. Harwood Academic
Publishers. 1997: 31-42.
62) Hodgetts V, Coppack S, Frayn KN,
Hockaday TDR. Factors controlling fat mobilization from human
subcutaneous adipose tissue during exercise. J Appl Phys 1991;
63) Millet L, Barbe M, Lafontan M, Berlan M,
Galitzky J. Catecholamine effects on lipolysis and blood flow in human
abdominal and femoral adipose tissue. J Appl Physiol 1998;
64) Ruffolo RR, Bondinell W, Hieble JP. a - and b
-Adrenoceptors: From the gene to the clinic. 2. Structure-activity
relationships and therapeutic applications. J Med Chem 1995;
65) Arner P, Bolinder J. Microdialysis of adipose tissue. J Int Med 1991; 230:381-386.
66) Frayn KN, Fielding BA, Summers LKM. Investigation of human adipose tissue metabolism in vivo. J Endo 1997; 155:187-189.
Willette RN, Hieble JP, Sauermelch CF. The role of the alpha
adrenoceptor subtypes in sympathetic control of the acralcutaneous
microcirculation. J Pharmacol Exp Ther 1991; 256:599-605.
Borbujo J, Garcia-Villalon AL, Balle J, et al. Postjunctional alpha-1
and alpha-2 adrenoceptors in human skin arteries. An in vitro study. J
Pharmacol Exp Ther 1989; 249:284-287.
69) Galitzky J, Lafontan
M, Nordenstrom J, Arner P. Role of vascular alpha-2 adrenoceptors in
regulating lipid mobilization from human adipose tissue. J Clin Invest
70) Horn PT, Kohli JD, Listinsky JJ,
Goldberg LI. Regional variation in the alpha-adrenergic receptors in the
canine resistance vessels. Nauyn-Schmiedeberg’s Arch Pharmacol 1982;
71) Flavahan NA, Cooke JP, Shepherd JT, Vanhoutte
PM. Human postjunctional alpha-1 and alpha-2 adrenoceptors: differential
distribution in arteries of the limbs. J Pharmacol Exp Ther 1987;
72) Glusa E, Markwardt F. Characterization of
postjunctional alpha-adrenoceptors in isolated human femoral veins and
arteries. Nauyn-Schmiedeberg’s Arch Pharmacol 1983; 323:101-105.
Enoksson S, Nordenstrom J, Bolinder J, Arner P. Influence of local
blood flow on glycerol levels in human adipose tissue. Int J Obesity
74) Kovach AGB, Kovach E, Sandor P, et al.
Metabolic responses to localized ischemia in adipose tissue. J Surg Res
75) Barbe P, Galitzky J, Riviere D, Senard JM,
et al. Effects of physiological and pharmaceutical variation of
sympathetic nervous system on plasma non-esterified fatty acid
concentrations in man. Br J Pharm 1993; 36:25-30.
VV, Lonnqvist F, Thorne A, et al. Noradrenaline-induced lipolysis in
isolated mesenteric, omental and subcutaneous adipocytes from obese
subjects. Int J Obesity 1997; 21:972-979.
77) Arner P. Regulation of lipolysis in fat cells. Diab Rev 1996; 4:450-463.
78) Bjorntorp P. Obesity and the adipocyte. Neuroendocrine factors in obesity. J Endocrin 1997; 155:193-195.
Abate N, Garg A. Heterogeneity in adipose tissue metabolism: causes,
implications, and management of regional adiposity. Prog Lipid Res 1995;
80) Maurige P, et al. Regional difference in adipose
tissue lipolysis from lean and obese women: existence of postreceptor
alterations. Am J Physiol 1995 Aug; 269(2 pt 1): E341-E350.
Hellstrom L, Blaak E, Hagstrom-Toft E. Gender differences in adrenergic
regulation of lipid mobilization during exercise. Int J Sports Med
82) Goldberg MR Robertson D. Yohimbine: a
pharmacological probe for study of the a 2-adrenoceptor. Pharmacol Rev
83) Berlan M, Galitzky J, Riviere D, et al.
Plasma catecholamine levels and lipid mobilization induced by yohimbine
in obese and non-obese women. Int J Obesity 1991; 15:305-315.
Galitzky J, Taouis M, Berlan M, Riviere D, et al. a 2-Antagonist
compounds and lipid mobilization: evidence for a lipid mobilizing effect
oral yohimbine in healthy male volunteers. Eur J Clin Invest 1988;
85) Galitzky j, Riviere D, Tran MA, Montastruc JL,
Berlan M. Pharmacodynamic effects of chronic yohimbine treatment in
healthy volunteers. Eur J Clin Pharmacol 1990; 39:447-451.
86) Kuchio C, Jonderdo K, Piskorska D. Does yohimbine act as a slimming drug? Isr J Med Sci 1991; 27:550-556.
Zahorska-Markiewiz B, Kuchio, Piskorska D. Adrenergic control of
lipolysis and metabolic responses in obesity. Horm Metabol Res. 1986;
88) Murburg MM, Villacres EC, Ko BN, Veith RC.
Effects of yohimbine on human sympathetic nervous system function. J
Clin Endocrin Metab 1991; 73:861-865.
89) Sax L. Yohimbine does not affect fat distribution in men. Int J Obesity 1991; 3:261-280.
90) Bulow J. Adipose tissue blood flow during exercise. Dan Med Bull 1983; 30:85-100.
Bulow J, Madsen J. Regulation of fatty acid mobilization from adipose
tissue during exercise. Scand J Sports Sci 1986; 8:19-26.
Bulow J, Madsen J, Astrup A, Christensen NJ. Vasoconstrictor effect of
high FFA/albumin ratios in adipose tissue in vivo. Acta Physiol Scand
93) Berlan M, Montastruc JL, Lafontan M.
Pharmacological prospects for a 2-adrenoceptor antagonist therapy. TiPS
Rev 1992; 13:277-282.
94) Montastruc P, Belan M, Monstastruc
JL. Effect of yohimbine on submaxiallary salivation in dogs. Br. J
Pharmac 1989; 98:101-104.
95) Chatelut E, Rispail Y, Berlan M,
Montastruc JL. Yohimbine increases human salivary secretion. Br J Clin
Pharmac 1989; 366-368.)
96) Fiaramonti J, Berlan M, Fargeas MJ,
Bueno L. Yohimbine stimulates colonic motility through a central action
in conscious dogs. J Gastrointes Mot 1992; 4:137-141.
Charney DS, Heninger GR, Breier A. Noradrenergic function in panic
anxiety. Effects of yohimbine in healthy subjects and patients with
agoraphobia and panic disorder. Arch Gen Psychiatry 1984; 41:751-763.
Murburg MM, Villacres EC, Ko BN, Veith RC. Effects of yohimbine on
human sympathetic nervous system function. J Clin Endocrin Metab 1991;
99) Grunhaus L, Tiongco D, Zelnik T, Flegel P, et
al. Intravenous yohimbine. Selective enhancer of norepinephrine and
cortisol secretion and systolic blood pressure in humans. Clin
Neuropharmacol 1989; 12:106-114.
Henninger GR, Charney DS, Price LH. a 2-Adrenergic receptor sensitivity
in depression. The plasma MHPG, behavioral and cardiovascular responses
to yohimbine. Arc Gen Psychiatry 1988; 45:718-726.
McDougle CJ, Krystal JH, Price LH, Heninger GR, et al.
Noradrenergic response to acute ethanol administration in healthy
subjects: comparisons with intravenous yohimbine. Psychopharmacol 1995;
102) Betz, JM, White KD. Gas
chromatographic determination of yohimbine in commercial yohimbine
products. J AOAC Int. 1995; 78:1189-1194.
Benedek IH, Blouin RA, McNamara PJ. Serum protein binding and the
role of increased alpha1-acid glycoprotein in moderately obese subjects.
Br J Clin Pharmacol 1984; 18:941-946.
Guthrie SK, Hariharan M, Grunhaus LJ. Yohimbine bioavailability in
humans. Eur J Clin Pharmacol 1990; 39:409-411.
Hedner T, Edgar B, Edvinsson L, Hedner J, et al. Yohimbine
pharmacokinetics and interaction with the sympathetic nervous system in
normal volunteers. Eur J Clin Pharmacol 1992; 43:651-656.
Owen JA, Hakatsu SL, Fenemore J, Condra M, et al.
The pharmacokinetics of yohimbine in man. Eur J Clin Pharmacol 1987;
107) Le Verge R, Le Corre P,
Chevanne F. Determination of yohimbine and its two hydroxylated
metabolites in humans by high-performance liquid chromatography and mass
spectral analysis. J Chromatog 1992; 574:283-292.
Brannan T, Martinez-Tica J, Yahr MD. Effect of yohimbine on
brain monoamines: an in vivo study. J Neural Transm 1991; 3:81-87.
Hubbard JW, Pfister SL, Beidinger Am, Herzig TC,
et al. The pharmacokinetic properties of yohimbine in the conscious rat.
Naunyn-Schmiedeberg’s Arch Pharmacol 1988; 337:583-587.
110) University of Michigan Cardiovascular Center